Analysis of Immune Profiles Related to Disease Severity in COVID-19 by Flow Cytometry
暂无分享,去创建一个
M. Kızılgun | C. Artuk | S. Oren | F. Şahiner | M. Yavuz | Gamze İçen | Tuğrul Hoşbul | R. Gumral | Tugba Fatsa | S. Şenkal | C. Aydoğan | İrem Unat
[1] D. Leaf,et al. Therapeutic advances in COVID-19 , 2022, Nature Reviews Nephrology.
[2] Ruchong Chen,et al. Identification of Parameters Representative of Immune Dysfunction in Patients with Severe and Fatal COVID-19 Infection: a Systematic Review and Meta-analysis , 2022, Clinical Reviews in Allergy & Immunology.
[3] Serpil Öcal. SARS‐CoV‐2 and lung injury: Dysregulation of immune response but not hyperimmune response as in “cytokine storm syndrome” , 2021, The clinical respiratory journal.
[4] J. Hsu,et al. Interleukin-18 Is a Potential Biomarker to Discriminate Active Adult-Onset Still’s Disease From COVID-19 , 2021, Frontiers in Immunology.
[5] B. Paiva,et al. Immunological Biomarkers of Fatal COVID-19: A Study of 868 Patients , 2021, Frontiers in Immunology.
[6] Guangwei Luo,et al. The Inflammatory Factors Associated with Disease Severity to Predict COVID-19 Progression , 2021, The Journal of Immunology.
[7] F. Conti,et al. Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection , 2020, Frontiers in Pharmacology.
[8] P. Muñoz,et al. Lymphocyte subsets early predict mortality in a large series of hospitalized COVID‐19 patients in Spain , 2020, Clinical and experimental immunology.
[9] L. Cosmi,et al. Cell‐mediated and humoral adaptive immune responses to SARS‐CoV‐2 are lower in asymptomatic than symptomatic COVID‐19 patients , 2020, European journal of immunology.
[10] Chengliang Zhu,et al. Descriptive, Retrospective Study of the Clinical Characteristics of Asymptomatic COVID-19 Patients , 2020, mSphere.
[11] E. Zaboli,et al. Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID‐19 patients: Clinical and laboratory characteristics , 2020, Journal of medical virology.
[12] Daxian Wu,et al. Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients , 2020, BMC Infectious Diseases.
[13] Nicolas Carlier,et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients , 2020, Science.
[14] G. Mosayebi,et al. Increased expression of CD8 marker on T-cells in COVID-19 patients , 2020, Blood Cells, Molecules, and Diseases.
[15] Theodora Psaltopoulou,et al. Hematological findings and complications of COVID‐19 , 2020, American journal of hematology.
[16] G. Zini,et al. Morphological anomalies of circulating blood cells in COVID‐19 , 2020, American journal of hematology.
[17] Q. Ye,et al. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.
[18] Mario Plebani,et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis , 2020, Clinical chemistry and laboratory medicine.
[19] Q. Ye,et al. The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.
[20] R. Alizadeh-Navaei,et al. Evaluation of Hepatic Enzymes Changes and Association with Prognosis in COVID-19 Patients , 2020, Hepatitis Monthly.
[21] Allen M. Khakshooy,et al. CoViD-19 Immunopathology and Immunotherapy , 2020, Bioinformation.
[22] Zhiyong Ma,et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.
[23] M. Girardis,et al. SARS‐CoV‐2, the Virus that Causes COVID‐19: Cytometry and the New Challenge for Global Health , 2020, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[24] D. Wang,et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.
[25] A. M. Leontovich,et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 , 2020, Nature Microbiology.
[26] K. Yuen,et al. Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.
[27] H. Rothan,et al. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak , 2020, Journal of Autoimmunity.
[28] Lijuan Xiong,et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients , 2020, EBioMedicine.
[29] Yan Zhao,et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.
[30] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[31] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[32] Qin Ning,et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 , 2020 .